About GelMEDIX
GelMEDIX is a private company based in Cambridge, Massachusetts. It has reported $10,080,339 raised in four offerings on Form D since June 2020. Its chief executive is Max Cotler.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 1, 2025 | Oct 14, 2025amended Apr 30, 2026 | $747,000of $2.5M target | 5 | $149K | EquityRule 506(b) | Form D/A ↗2 earlier filings |
| Jan 24, 2025 | Feb 4, 2025 | $1,000,000of $4.0M target | 2 | $500K | Debt, OptionsRule 506(b) | Form D ↗ |
| Mar 11, 2024 | Mar 26, 2024 | $1,893,339of $3.5M target | 17 | $111K | DebtRule 506(b) | Form D ↗ |
| Jun 4, 2020 | Jun 19, 2020amended Aug 10, 2022 | $6,440,000of $8.0M target | 4 | $1.6M | Debt, OptionsRule 506(b) | Form D/A ↗2 earlier filings |
| Total, four offerings | $10,080,339 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on GelMEDIX's Form D filed Apr 30, 2026.
Earlier filings also listed Arthur Driscoll (president and director, last listed Aug 2022).